Ezrin expression in rectal cancer predicts time to development of local recurrence

International Journal of Colorectal Disease

Volumn 27, Issue 7, 2012, Pages 893-899

  Jörgren, Fredrik ^a,b   Nilbert, Mef ^b,c,d,e   Rambech, Eva ^b,c   Bendahl, Pär Ola ^b,c   Lindmark, Gudrun ^a  

^a HELSINGBORG HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d HVIDOVRE HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Ezrin; Local; Neoplasm recurrence; Prognostic; Rectal neoplams; Risk factors; Tumour marker

Indexed keywords

ANTINEOPLASTIC AGENT; EZRIN;

ABDOMINAL SURGERY; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECTUM CANCER; RECURRENCE RISK; RECURRENT CANCER; TIME TO LOCAL RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CYTOSKELETAL PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RECTAL NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84864453305     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-011-1397-z     Document Type: Article

References (30)

1. OK Wibe A, Carlsen E, Dahl O, Tveit KM, Weedon-Fekjaer H, Hestvik UE, Wiig JN; Norwegian Rectal Cancer Group (2006) Nationwide quality assurance of rectal cancer treatment. Colorectal Dis 8:224-229
2. Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, RuttenH, Pahlman L, Glimelius B, Leer JW, van deVelde CJ, Dutch Colorectal Cancer Group (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693-701
3. OK Pahlman L, Bohe M, Cedermark B, Dahlberg M, Lindmark G, Sjödahl R, Öjerskog B, Damber L, Johansson R (2007) The Swedish Rectal Cancer Registry. Br J Surg 94:1285-1292
4. OK Jörgren F, Johansson R, Damber L, Lindmark G (2010) Risk factors of rectal cancer local recurrence: population-based survey and validation of the Swedish Rectal Cancer Registry. Colorectal Dis 12:977-986
5. OK Boland CR, Goel A (2010) Microsatellite instability in colorectal cancer. Gastroenterology 138:2073-2087
6. OK Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ (2004) The membrane- cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10:182-186
7. OK Tynninen O, Carpén O, Jääskeläinen J, Paavonen T, Paetau A (2004) Ezrin expression in tissue microarray of primary and recurrent gliomas. Neuropathol Appl Neurobiol 30:472-477
8. OK Weng WH, Ahlén J, Aström K, Lui WO, Larsson C (2005) Prognostic impact of immunohisto-chemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 11:6198-6204
9. OK Köbel M, Gradhand E, Zeng K, Schmitt WD, Kriese K, Lantzsch T, Wolters M, Dittmer J, Strauss HG, Thomssen C, Hauptmann S (2006) Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. Int J Gynecol Pathol 25:121-130
10. OK Bruce B, Khanna G, Ren L, Landberg G, Jirström K, Powell C, Borczuk A, Keller ET, Wojno KJ, Meltzer P, Baird K, McClatchey A, Bretscher A, Hewitt SM, Khanna C (2007) Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 24:69-78
11. Brambilla D, Fais S (2009) The Janus-faced role of ezrin in "linking" cells to either normal or metastatic phenotype. Int J Cancer 125:2239-2245
12. OK Xie JJ,Xu LY, XieYM, ZhangHH, CaiWJ, Zhou F, Shen ZY, LiEM (2009) Roles of ezrin in the growth and invasiveness of esophageal squamous carcinoma cells. Int J Cancer 124:2549-2558
13. Cui Y, Li T, Zhang D, Han J (2010) Expression of Ezrin and phosphorylated ezrin (pEzrin) in pancreatic ductal adenocarcinoma. Cancer Invest 28:242-247
14. OK Vaheri A, Carpén O, Heiska L, Helander TS, Jää skeläinen J, Majander-Nordenswan P, Sainio M, Timonen T, Turunen O (1997) The ezrin protein family: membrane-cytoskeleton interactions and disease associations. Curr Opin Cell Biol 9:659-666
15. OK Hiscox S, Jiang WG (1999) Ezrin regulates cell-cell and cell- matrix adhesion, a possible role with E-cadherin/beta-catenin. J Cell Sci 112:3081-3090
16. Hunter KW (2004) Ezrin, a key component in tumor metastasis. Trends Mol Med 10:201-204
17. OK Fehon RG, McClatchey AI, Bretscher A (2010) Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 11:276-287
18. Yan G, Zhou X, Xiao X, Lu H, Du X (2007) Ezrin expression and its translocation in human primary sporadic colorectal carcinoma and prognostic significance. Chinese-German J Clin Oncol 6:232-236
19. Nowak D, Mazur AJ, Popow-Woźniak A, Radwańska A, Mannherz HG, Malicka-Błaszkiewicz M (2010) Subcellular distribution and expression of cofilin and ezrin in human colon adenocarcinoma cell lines with different metastatic potential. Eur J Histochem 54:59-66
20. OK Gavert N, Ben-Shmuel A, Lemmon V, Brabletz T, Ben-Ze'ev A (2010) Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J Cell Sci 123:2135-2143
21. OK Elzagheid A, Korkeila E, Bendardaf R, Buhmeida A, Heikkilä S, Vaheri A, Syrjänen K, Pyrhönen S, Carpén O (2008) Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer. Hum Pathol 39:1737-1743
22. OK Wang HJ, Zhu JS, Zhang Q, Sun Q, Guo H (2009) High level of ezrin expression in colorectal cancer tissues is closely related to tumor malignancy. World J Gastroenterol 15:2016-2019
23. OK Korkeila EA, Syrjänen K, Bendardaf R, Laulajainen M, Carpén O, Pyrhönen S, Sundström J (2011) Preoperative radiotherapy modulates ezrin expression and its value as a predictive marker in patients with rectal cancer. Hum Pathol 42:384-392
24. OK JungEJ, Lee JH, MinBW, KimYS,Choi JS (2011) Clinicopathologic significance of fascin, extracellular matrix metalloproteinase inducer, and ezrin expressions in colorectal adeno-carcinoma. Indian J Pathol Microbiol 54:32-36
25. OK He ZY, Wen H, Shi CB, Wang J (2010) Up-regulation of hnRNP A1, Ezrin, tubulin β-2 C and Annexin A1 in sentinel lymph nodes of colorectal cancer. World J Gastroenterol 16:4670-4676
26. OK Holm T, Cedermark B, Rutqvist LE (1994) Local recurrence of rectal adenocarcinoma after 'curative' surgery with and without preoperative radiotherapy. Br J Surg 81:452-455
27. OK Merkel S, Mansmann U, Hohenberger W, Hermanek P (2011) Time to locoregional recurrence after curative resection of rectal carcinoma is prolonged after neoadjuvant treatment. A systematic review and meta-analysis. Colorectal Dis 13:123-131
28. OK Yao Y, Jia XY, Tian HY, Jiang YX, Xu GJ, Qian QJ, Zhao FK (2009) Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. Biochim Biophys Acta 1794:1433-1440
29. OK Rebillard A, Jouan-Lanhouet S, Jouan E, Legembre P, Pizon M, Sergent O, Gilot D, Tekpli X, Lagadic-Gossmann D, Dimanche-Boitrel MT (2010) Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells. Eur J Cancer 46:1445-1455
30. OK Blomqvist L, Glimelius B (2008) The 'good', the 'bad', and the 'ugly' rectal cancers. Acta Oncol 47:5-8